InvestorsHub Logo
Followers 1184
Posts 134793
Boards Moderated 3
Alias Born 08/27/2003

Re: drkazmd65 post# 119986

Wednesday, 04/13/2016 5:29:46 PM

Wednesday, April 13, 2016 5:29:46 PM

Post# of 146211
Post of the month deserves repeating:

loanranger Member Level Wednesday, 04/13/16 06:30:51 AM
Re: drkazmd65 post# 119889
Post #
119949
of 119989 Go
"Plenty of things "of substance" have been accomplished."

That's what you say. I don't agree. In the absence of a fancy degree I have to rely on what I think makes sense..."the proof is in the pudding" has proven to be not just sensible but a pretty decent investment guideline.

Tamiflu was approved in 1999. It is on the World Health Organization's List of Essential Medicines. The man in charge of the science at NanOviricides, Anil Diwan, used it perfectly appropriately as a reference point in a presentation at the PUBLIC MEETING ON NANOTECHNOLOGY MATERIALS IN FDA REGULATED PRODUCTS on Tuesday, October 10, 2006:
"in mouse studies we have shown that our drug....somewhere between 100 times better than Tamiflu in efficacy"
http://www.fda.gov/ohrms/dockets/dockets/06n0107/06n-0107-tr00001.pdf


In the 10 years since NNVC Chairman and President Diwan made that statement BILLIONS of dollars worth of Tamiflu (oseltamivir) have been sold. A year before Diwan spoke those words U.S. President George W. Bush requested that Congress fund US$1 billion for the production and stockpile of oseltamivir, after Congress had already approved $1.8 billion for military use of the drug.


There have been excuses galore for the failure of NNVC to bring the drug that was purportedly "somewhere between 100 times better than Tamiflu in efficacy" to market. The whole giant stinking pile of excuses doesn't add up to a decent explanation for that failure. We are constantly reminded of how long it takes to develop a drug to the point of approval. The company 10-K explains that "These clinical trials involve three separate phases that often overlap, can take many years to compile and are very expensive." The company has never progressed to the point where they even BEGAN that process in the case of a drug that was asserted to be 100 times better than the multi-billion dollar drug that it was compared to.




"Plenty of things "of substance" have been accomplished."
The most substantial company accomplishment to date has been its compilation of excuses for its failures with its archive of changes of direction running a close second.

The SwingTrade Portfolio was up 36.2% in 2014, 83.5% in 2013, and 546.6% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110307454

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News